Integrated Biosciences, Inc.

We’re #hiring for extraordinary Research Associates, a Head of Chemistry, and a Head of Business Development. For more information, please visit the links below. We look forward to hearing from you! Careers: https://lnkd.in/gm88ec7b Research Associate position: https://lnkd.in/gFRbrZdm Head of Chemistry position: https://lnkd.in/gCEzkkbQ Head of Business Development position: https://lnkd.in/gFrWZzc2

Integrated Biosciences welcomes Illumina Ventures to the family! Our partnership with Illumina Ventures Labs will integrate the company’s drug discovery engine with Illumina sequencing, enabling us to discover and design new classes of small molecule therapeutics that act by shaping the transcriptomes and methylomes of cell populations. These drug candidates will be applicable to diverse diseases for which cell state and identity are important, including diseases related to aging and development. #aging #DNA #RNA #drugdiscovery https://lnkd.in/gFnPQs2b

I’m thrilled to share the highlight of my scientific career to date, our most recent study from Integrated Biosciences, Inc., MIT, and the Broad Institute, published in Nature! In it, we describe the first-ever class of antibiotics discovered with explainable deep learning, one of the few overall to have been discovered in the past 60 years. This is a breakthrough result showing that explainable deep learning can uniquely catalyze drug discovery, and one of the first demonstrations that deep learning models can explain what they predict, with immediate and far-reaching implications to how drug discovery is done and how efficiently we can find new drugs using AI. We drew inspiration from DeepMind’s AlphaGo to develop these explainable models, which now allow us to downsample the effectively infinite search space for new drugs. Our new class of antibiotics is more than a proof-of-concept: we tested it in mouse models of MRSA infection and found that it was efficacious both topically and systemically, indicating that it could be suitable for further development as a treatment even for severe and sepsis-related bacterial infections. This work was made possible by an international team of 21 researchers led by myself and Jim Collins at MIT. It demonstrates just one of the key components of Integrated Biosciences’ platform (which Integrated Biosciences is applying to target aging) and would not have been possible without our believers, including Root Ventures, Mission BioCapital, Conscience VC, Reinforced Ventures, and Polymath Capital. Thank you again to all who believed in us. Paper: https://lnkd.in/gkWQtGBU Research briefing: https://lnkd.in/gEQbxwyA Press release: https://lnkd.in/gsaKsxe6 Integrated Biosciences’ website: https://lnkd.in/ge8EBjBg Direct link to the paper: https://lnkd.in/gsPDH-dB #antibiotics #ai #aging #artificialintelligence #integratedbiosciences #machinelearning #broadinstitute #mit Integrated Biosciences, Inc.